How to Balance New vs Experienced Investigators in Clinical Trials

Introduction: The Strategic Choice Between Experience and Opportunity

Principal Investigator (PI) selection is one of the most critical aspects of clinical trial feasibility and site planning. Sponsors and CROs often face the dilemma of choosing between highly experienced investigators—who bring proven track records but may be overextended—and newer investigators, who may offer enthusiasm, available bandwidth, and access to untapped patient populations but lack extensive trial history. Balancing new and experienced PIs in a trial portfolio is both a science and an art, requiring structured evaluation, risk mitigation, and long-term planning.

This article explores the considerations, risks, and opportunities in balancing new versus experienced investigators, and provides tools to guide sponsors and CROs in building sustainable and diverse investigator networks.

1. Defining “New” vs “Experienced” Investigators

Experienced Investigators typically meet criteria such as:

• Served as PI or Sub-Investigator on 5+ prior studies
• Experience with the therapeutic area of interest
• Proven track record in meeting recruitment targets
• Documented inspection history and audit readiness

New Investigators may include:

• First-time PIs transitioning from sub-investigator roles
• Academic physicians with strong patient populations but no prior trial experience
• Specialists in emerging therapeutic areas or rare diseases with limited historical trial exposure

Both groups have unique advantages and risks, which must be assessed systematically.

2. Advantages of Experienced Investigators

Experienced PIs provide multiple benefits:

• Strong knowledge of GCP and regulatory requirements
• Operationally mature sites with trained staff
• Faster study start-up due to familiarity with documentation
• Proven ability to navigate monitoring and inspections

Example: In a cardiology Phase III study, experienced PIs enrolled subjects 30% faster and had 40% fewer protocol deviations compared to less experienced peers.

3. Risks and Challenges of Experienced Investigators

Despite their strengths, experienced investigators also pose challenges:

• Overcommitment across multiple concurrent studies
• Potential recruitment fatigue within their patient pool
• Lower enthusiasm for less prestigious or small-budget trials
• Complacency in documentation or training compliance

These risks underscore the importance of evaluating investigator workload and availability during feasibility.

4. Advantages of New Investigators

Engaging new PIs can provide unique opportunities:

• Access to new patient populations and referral networks
• High motivation to establish themselves in clinical research
• Willingness to adopt new technologies and decentralized models
• Expansion of sponsor’s investigator pool for future studies

Case Study: A sponsor in dermatology recruited two first-time PIs from community hospitals. Both exceeded recruitment targets by leveraging previously untapped patient bases, improving diversity in trial enrollment.

5. Risks of New Investigators

New investigators bring enthusiasm but also risks:

• Inexperience with regulatory submissions and startup timelines
• High learning curve in GCP and trial operations
• Need for intensive sponsor/CRO training and monitoring
• Increased risk of protocol deviations and inspection findings

Without structured support, new PIs may compromise data integrity or trial timelines.

6. Balancing Strategies: Portfolio-Level Approach

Sponsors should not treat PI selection as an either/or choice. Instead, balance is achieved by:

• Mixing New and Experienced PIs: Assign high-risk protocols to experienced PIs and low-complexity studies to new ones
• Geographic Diversity: Use new PIs to enter untapped regions, paired with experienced PIs for stability
• Mentorship Models: Pair new PIs with experienced Sub-Is in the same study
• Phased Engagement: Start new PIs with smaller studies or sub-investigator roles before assigning pivotal trials

This approach builds a resilient network and reduces overreliance on a small set of experienced investigators.

7. Tools for Assessing PI Balance

Structured tools help evaluate how new vs experienced PIs should be allocated:

The composite score helps sponsors determine the optimal PI mix per study.

8. Regulatory and Ethical Considerations

Engaging new investigators is aligned with regulatory calls for diversity and inclusivity:

• FDA Diversity Guidance (2022): Encourages expanding networks to include community and minority-serving physicians
• ICH E8(R1): Emphasizes generalizability of trial data through broad investigator engagement
• EMA Guidance: Supports recruitment beyond academic centers to capture real-world practice diversity

Balancing PI selection therefore serves both operational and regulatory goals.

9. Case Example: Mixed PI Engagement in Rare Disease Trial

A biotech company conducting a rare disease trial engaged both academic KOLs (experienced PIs) and first-time PIs at regional specialty centers. While the KOLs brought scientific credibility, the regional new PIs provided patient access that doubled recruitment diversity. Intensive CRA oversight and sponsor-led training ensured compliance.

Outcome: Recruitment targets were achieved ahead of schedule, and regulators commended the sponsor’s inclusive site network strategy.

Conclusion

Balancing new versus experienced investigators is a strategic imperative in clinical trial planning. Experienced PIs bring reliability and regulatory security, while new PIs provide access to fresh populations and long-term network expansion. By implementing mentorship models, phased onboarding, and structured evaluation tools, sponsors can harness the strengths of both groups. The result is a diversified, resilient investigator pool that ensures trial feasibility, compliance, and patient inclusivity for current and future studies.

Remote Approaches for Evaluating Clinical Site Capabilities During Feasibility

Introduction: Shifting from On-Site to Remote Capability Assessments

The COVID-19 pandemic accelerated the adoption of remote and digital approaches in clinical research operations, including feasibility assessments and site qualification. Even post-pandemic, the use of remote methods to evaluate clinical site capabilities remains highly relevant due to cost savings, operational flexibility, and global trial complexity. Sponsors and CROs now conduct virtual site evaluations using teleconferencing, document sharing platforms, e-questionnaires, and remote facility walkthroughs to determine site readiness for clinical trials.

These remote methods must still comply with regulatory expectations and Good Clinical Practice (GCP) guidelines, while ensuring that sponsors adequately assess investigator qualifications, infrastructure, SOPs, technology readiness, and enrollment feasibility. This article provides a structured overview of remote methods for evaluating site capabilities, including benefits, limitations, digital tools, documentation practices, and best practices for inspection readiness.

1. Scope and Objectives of Remote Site Capability Assessments

Remote site assessments serve the same core purposes as on-site audits:

• Confirming investigator qualifications and experience
• Evaluating staffing, infrastructure, and SOP availability
• Reviewing technology readiness (e.g., EDC access, eConsent tools)
• Assessing enrollment potential and competing trial burden
• Ensuring regulatory and ethics committee preparedness

Remote assessments may be conducted as the sole method of feasibility or as a supplement to on-site audits, especially in decentralized, global, or hybrid trials.

2. Digital Tools and Platforms for Remote Evaluation

Several technologies enable effective remote feasibility and capability assessments:

• eFeasibility Platforms: Centralized systems for sending, collecting, and analyzing feasibility questionnaires (e.g., Clario, Veeva, TrialHub)
• Video Conferencing Tools: Used for live PI and staff interviews (e.g., Zoom, Microsoft Teams, Webex)
• Secure Document Sharing: For reviewing SOPs, CVs, calibration logs, and training records (e.g., SharePoint, Box, Dropbox Business)
• Virtual Facility Tours: Pre-recorded videos or live walkthroughs to inspect clinical and pharmacy areas
• Digital Signature Tools: For validating signed documents (e.g., DocuSign, Adobe Sign) compliant with 21 CFR Part 11

These tools must be validated where applicable and aligned with data privacy laws such as GDPR or HIPAA.

3. Components of a Remote Site Capability Assessment

During a remote feasibility process, sponsors should evaluate the following elements:

3.1 Investigator Qualifications and Oversight

• Request signed and dated CVs with therapeutic area experience
• Confirm GCP training within the past 24 months
• Schedule video interviews with PI and study coordinator
• Assess time allocation for trial and competing study load

3.2 Staffing and Infrastructure Review

• Request staffing matrix and delegation of duties template
• Collect site organizational chart and training logs
• Review equipment inventory and calibration certificates remotely
• Conduct virtual tour of IP storage room, exam rooms, lab areas

3.3 SOP and Quality Systems Documentation

• Request SOP index and sample SOPs (e.g., AE reporting, IP handling)
• Verify approval dates, version control, and review cycles
• Check SOP training records and acknowledgment logs

3.4 Technology Readiness

• Test access to sponsor platforms (EDC, IRT, eTMF)
• Verify internet stability and data security practices
• Assess familiarity with remote monitoring tools
• Ensure compatibility with eConsent, ePRO, and telehealth systems

3.5 Ethics Committee and Regulatory Preparedness

• Request past EC approval letters with turnaround times
• Confirm IRB registration status and contact details
• Discuss submission cycles and review schedules
• Clarify local regulatory steps, especially for global sites

4. Sample Remote Audit Summary Table

5. Regulatory Compliance in Remote Feasibility

Remote assessments must meet the same GCP and documentation requirements as in-person evaluations. Regulatory expectations include:

• Maintaining documented evidence of all remote assessments
• Version-controlled checklists and signed audit summaries
• Secure transmission and storage of shared files
• Recording video calls where permitted and logging attendance
• Ensuring systems used are Part 11 / Annex 11 compliant where applicable

The FDA, EMA, and MHRA have all published guidance supporting remote monitoring and oversight, especially in hybrid and decentralized models. Tools and processes used must be included in the sponsor’s TMF and internal SOPs.

6. Advantages of Remote Site Capability Assessments

• Cost-effective, especially for global and emerging markets
• Faster scheduling and turnaround time
• Enables review of more sites during early-stage feasibility
• Reduces travel burden and carbon footprint
• Supports decentralized trial models

7. Challenges and Limitations

• May miss facility details not visible via video
• Some sites lack technical capability or digital experience
• Potential data privacy risks during document sharing
• Subjective assessment of cleanliness, temperature logs, equipment state

Remote assessments may not fully replace on-site visits, especially for high-risk or first-time sites. A hybrid model may be more appropriate in such cases.

8. Best Practices for Remote Feasibility Teams

• Use a standardized remote audit checklist with clear pass/fail criteria
• Schedule structured video calls with predefined agenda
• Assign a tech coordinator to assist the site with video tours or file uploads
• Maintain a real-time tracker of document receipt and pending actions
• Ensure all activities are logged and archived in TMF with access audit trails

9. Real-World Example: Remote Assessment in Asia-Pacific Region

In a Phase III vaccine trial, a sponsor used remote feasibility methods to assess 28 sites across India, Vietnam, and Malaysia. The sponsor deployed eFeasibility tools and conducted structured Zoom interviews. While 5 sites were excluded due to lack of cold chain documentation or poor internet access, 23 were qualified and activated within 21 days—70% faster than previous trials. Remote methods enabled quick rollout while maintaining compliance and quality.

Conclusion

Remote methods for evaluating clinical site capabilities offer a flexible, scalable, and cost-effective alternative to traditional on-site audits. With the right tools, structured procedures, and documentation controls, sponsors and CROs can ensure a thorough and compliant feasibility process that supports modern clinical trial models. As digital trials continue to expand, remote feasibility will remain a core competency for clinical operations and regulatory teams alike.

How to Evaluate Principal Investigator Experience in Feasibility Questionnaires

Why PI Experience Is Critical to Trial Success

The success of any clinical trial relies significantly on the capabilities of the Principal Investigator (PI). A well-qualified PI ensures proper protocol execution, adherence to Good Clinical Practice (GCP), efficient patient recruitment, and timely data entry. As such, assessing PI experience during the feasibility process is a regulatory and operational necessity. Regulatory authorities like the FDA, EMA, and PMDA emphasize robust PI qualification checks during inspections and sponsor audits.

Feasibility questionnaires are a primary tool for gathering critical information on PI qualifications, experience, and history. If designed correctly, they provide insights into whether a site has the leadership and clinical expertise to conduct the study. Poorly evaluated PIs can lead to protocol deviations, delayed timelines, and even inspection findings.

This article explores the key elements to assess PI experience through feasibility questionnaires, including document review, scoring methods, red flags, and regulatory alignment.

Core Domains to Evaluate PI Experience

A comprehensive feasibility questionnaire should assess multiple dimensions of a PI’s capability:

• Clinical Trial Experience: Number and type of trials conducted (Phase I–IV)
• Therapeutic Area Specialization: Alignment with the protocol indication
• Regulatory History: Inspections, 483 observations, or GCP violations
• Training Credentials: GCP certifications and investigator training logs
• Site Oversight Capacity: Number of trials currently managed

Example questions in a feasibility survey might include:

Document Verification: Going Beyond the Survey

Questionnaire responses alone are not sufficient. Sponsors must request and verify supporting documentation:

• Signed and dated PI CV (within past 2 years)
• GCP certification (ICH E6-compliant, dated within past 2 years)
• Training logs for protocol-specific modules
• Documentation of PI delegation logs from past trials
• Inspection reports or audit summaries (if available)

These documents must be reviewed, archived in the eTMF, and aligned with feasibility questionnaire answers. Discrepancies—such as overstated experience or outdated GCP certificates—should be flagged for clarification before site selection.

For cross-validation, sponsors can refer to clinical trial registries such as ANZCTR to review PIs listed in past studies and compare enrollment timelines and completion status.

Scoring Systems for PI Evaluation

Many sponsors and CROs use scoring systems to quantify PI suitability during the feasibility phase. These scores are based on multiple weighted criteria:

PIs scoring below a predefined threshold (e.g., 70/100) may require additional review or exclusion from site consideration. The scoring model can be automated via CTMS-integrated feasibility platforms.

Red Flags in PI Feasibility Assessments

Watch for these common issues in questionnaire responses or supporting documents:

• PI CV missing or outdated
• More than 5 concurrent studies under PI oversight
• No evidence of protocol-specific training
• Prior inspection with unresolved CAPA
• Enrollment performance not aligned with feasibility estimates

Such red flags should trigger a follow-up interview or teleconference with the site to clarify discrepancies. Regulatory inspectors frequently review these inconsistencies when auditing site selection processes.

Case Study: Protocol Deviations Linked to Inadequate PI Oversight

In a Phase II oncology study, one investigator site experienced 14 protocol deviations within 3 months. Upon review, the feasibility questionnaire listed the PI as experienced, but later it was found that the PI had not attended protocol training and was concurrently managing 7 studies. FDA inspection identified this oversight as a major finding. The sponsor was required to implement new SOPs for PI qualification and conduct a full re-training across all sites.

Regulatory Expectations for PI Evaluation

According to ICH E6(R2), sponsors are required to:

• Evaluate PI qualifications and capability to oversee the trial (Section 5.6)
• Maintain up-to-date records of PI experience, CV, and training (Section 8.2)
• Ensure proper supervision of site staff and trial conduct (Section 4.2)

The FDA’s Bioresearch Monitoring Program also audits how PI qualifications were verified during feasibility and whether their involvement was adequately documented in the TMF.

Best Practices for PI Evaluation Through Questionnaires

• Customize PI sections in feasibility surveys based on protocol complexity
• Use weighted scoring systems for objective evaluation
• Digitally link PI questionnaire responses to their training and inspection history
• Require e-signatures on PI forms to ensure accountability
• Update PI evaluations at study milestones (e.g., mid-recruitment checkpoint)

Conclusion

Evaluating the Principal Investigator’s experience and qualifications is a cornerstone of effective clinical trial feasibility planning. Through well-designed feasibility questionnaires, sponsors can screen for both technical and regulatory competence, minimize risks of protocol violations, and improve trial outcomes. By implementing structured, compliant, and validated PI evaluation frameworks, sponsors not only meet regulatory expectations but also strengthen the foundation for high-quality trial execution.

Frequent Mistakes to Avoid When Designing Feasibility Surveys

Why Survey Design Matters in Clinical Feasibility

Feasibility surveys are the first checkpoint in clinical trial execution. Sponsors, CROs, and clinical teams rely on these tools to determine which investigator sites are capable of enrolling, complying, and delivering high-quality data. However, flawed survey design can compromise this entire process—leading to site underperformance, protocol deviations, missed enrollment targets, and costly delays. Regulatory authorities like the FDA and EMA have highlighted the importance of accurate feasibility assessments in multiple inspection reports.

Designing an effective feasibility questionnaire is not just about gathering information—it’s about ensuring the **quality, clarity, and relevance** of the data collected. Poor design choices can introduce bias, reduce response rates, and provide misleading inputs, ultimately affecting trial success.

This article explores common pitfalls in feasibility survey design and provides corrective strategies to improve accuracy, efficiency, and regulatory alignment.

1. Over-Reliance on Generic Questionnaires

One of the most frequent mistakes is using generic, one-size-fits-all surveys across all therapeutic areas and trial phases. This ignores the unique requirements of different indications. For example, asking only “Do you have imaging capabilities?” in an oncology trial overlooks critical aspects like:

• Type of imaging (CT, MRI, PET)
• RECIST or iRECIST measurement familiarity
• Archiving and transfer compliance (DICOM format)

Similarly, a vaccine trial might need cold chain logistics and mass-screening capacity questions, which may be completely irrelevant to a rare disease gene therapy study. Lack of customization can cause misaligned expectations and downstream failures.

2. Ambiguous or Leading Questions

Vague phrasing leads to inconsistent interpretation and invalid data. For instance, asking “Can you enroll patients quickly?” is subjective. What qualifies as “quick” for one site may differ from another. Instead, a better version would be:

“How many patients fitting the protocol inclusion criteria did your site enroll in the last 12 months for similar Phase II studies?”

Leading questions also bias the respondent. “You have successfully conducted previous trials, correct?” might trigger social desirability bias. Neutral, fact-based phrasing is key.

3. Excessive Length and Complexity

Lengthy surveys with poor flow reduce completion rates and frustrate site staff. In multi-center trials, sites often have limited staff availability, especially during active study periods. Surveys that take over 45 minutes are less likely to be completed accurately. Issues include:

• Redundant questions across sections
• Poor section organization (e.g., mixing regulatory and infrastructure questions)
• Lack of autosave or ability to pause and resume digital forms

As a best practice, limit questionnaires to 25–30 well-structured questions for initial feasibility, followed by site-specific deep dives as needed. Use digital platforms that allow intuitive navigation and validation.

4. Lack of Data Validation or Documentation Fields

Another flaw is the absence of cross-checks or request for supporting documentation. For example, if a site claims it can enroll 100 patients over 6 months, sponsors should request either:

• Patient registry screenshots
• De-identified electronic health record reports
• Recruitment logs from similar studies

Without these, responses are based solely on memory or estimates, increasing risk of over-promising. Platforms should include fields for file uploads, comment boxes for clarification, and warning prompts for unusual entries.

5. Ignoring Historical Site Performance Data

Failing to consider a site’s previous trial history is a major oversight. Historical data helps contextualize feasibility answers and filter out consistently underperforming sites. For example:

Integrating such data-driven benchmarking within the survey design significantly improves reliability and transparency.

Transition to Solutions and Best Practices

Now that we’ve identified major pitfalls in feasibility survey design, the next part will offer regulatory-aligned solutions, practical templates, and technology integrations to improve the quality of your feasibility assessments.

6. Neglecting to Capture PI and Sub-Investigator Details

Many feasibility surveys focus primarily on site-level infrastructure while ignoring investigator qualifications. Yet, the PI’s past experience, availability, and regulatory track record are critical success factors. A well-designed survey should capture:

• Number of trials conducted in the last 5 years
• Therapeutic area alignment with the protocol
• GCP training validity and inspection history
• Ratio of PI to concurrent active trials

Neglecting to gather such details could lead to site activation delays due to regulatory rejection of PI credentials or unavailability.

7. Overlooking Regional and Regulatory Context

Global feasibility surveys often ignore country-specific regulations and operational limitations. For example:

• In India, the CDSCO has specific rules regarding ethics approvals and compensation
• In Japan, feasibility surveys must include PMDA-specific compliance sections
• In the EU, surveys must align with EU Clinical Trial Regulation (CTR) timelines and document requirements

Not including such country-specific sections can result in inaccurate site feasibility outcomes. For global trials, it’s critical to tailor questions by region or include branching logic that triggers local regulatory queries based on country selection.

8. No Mechanism to Capture Feasibility Risk Flags

A robust feasibility survey should include logic or scoring that auto-generates red flags based on site responses. For instance:

Response	Flag
PI is involved in 7 concurrent studies	Investigator overload
Site has no GCP training in last 3 years	Non-compliance risk
Startup timeline > 90 days	High activation risk

Such automated risk indicators help feasibility managers prioritize follow-ups and site visits.

9. Lack of Digital Integration and Data Traceability

Paper-based or email surveys still exist in some trials, resulting in data loss, miscommunication, and lack of audit trails. Regulatory inspectors, including from the FDA, expect version control, date/time stamps, and investigator signatures on feasibility forms.

Surveys should be integrated into platforms like Veeva CTMS, Clario Feasibility, or other compliant digital tools. This enables audit-ready documentation and seamless comparison across protocols and regions.

10. Ignoring Site Feedback for Continuous Improvement

Finally, many sponsors and CROs fail to review site feedback post-survey. Sites may provide comments such as:

• “Questions are repetitive or unclear”
• “Form is too long for busy clinics”
• “Unable to attach required documents easily”

Incorporating this feedback into subsequent versions ensures higher response rates, better data, and improved sponsor-site collaboration. Sponsors should conduct post-survey reviews or pilot testing to optimize forms continuously.

Best Practice Recommendations

• Limit initial surveys to 25–30 critical questions
• Use digital tools with conditional logic and data upload fields
• Benchmark recruitment estimates with historical performance
• Customize by therapeutic area and regulatory region
• Include risk scoring and auto-flagging mechanisms
• Maintain an audit-ready record with version control and timestamps

Tools like Clinscape, TrialHub, and Medidata can help structure and automate these best practices into scalable survey systems.

Conclusion

Feasibility surveys are the foundation of successful clinical trials. Yet, poor design introduces risk, waste, and non-compliance. Sponsors and CROs must recognize and avoid the common pitfalls outlined above—generic questions, ambiguous wording, missing validations, and absence of risk flagging. By adopting best practices, leveraging digital platforms, and integrating historical data, sponsors can build robust, regulatory-aligned feasibility tools that drive accurate site selection and successful trial execution.

Essential Questions for Designing an Effective Feasibility Questionnaire

Understanding the Role of Feasibility Questionnaires

Before selecting sites and investigators, sponsors and CROs must carefully evaluate a site’s ability to successfully execute a clinical trial. A feasibility questionnaire is one of the most important tools for this assessment. These documents collect structured information about a site’s resources, patient pool, regulatory experience, and infrastructure readiness. Regulatory agencies such as the FDA, EMA, and national authorities expect sponsors to document feasibility efforts as part of Good Clinical Practice (GCP) compliance. Without a robust feasibility process, sponsors risk delays, under-enrollment, and inspection findings during trial audits.

Feasibility questionnaires typically cover domains such as:

• Patient recruitment and retention potential
• Principal Investigator (PI) and sub-investigator experience
• Site infrastructure, including equipment and labs
• Previous performance in similar therapeutic areas
• Local regulatory and ethics committee processes

For example, in oncology studies, questionnaires often probe whether the site has access to pathology labs capable of immunohistochemistry testing, or whether genetic testing partnerships exist. In infectious disease studies, questions may focus on availability of biosafety level facilities. Thus, while core domains remain consistent, therapeutic area–specific tailoring is essential.

Critical Patient-Related Questions

Patient recruitment is one of the most common barriers to timely trial completion. Regulators, including the European Medicines Agency (EMA), emphasize that feasibility assessments should be realistic and data-driven. A questionnaire must therefore ask targeted questions about patient populations. Examples include:

Incorporating epidemiological data strengthens these questions. For example, if a site estimates 300 eligible patients annually but national disease burden data suggests fewer than 50 cases in the region, this discrepancy raises concerns about overestimation. Sponsors should cross-check questionnaire responses with external databases such as ClinicalTrials.gov to validate feasibility claims against trial recruitment histories.

Questions on Investigator and Staff Experience

A site’s human resources are equally critical. Regulators often highlight inadequate investigator oversight as a frequent finding in inspections. Questionnaires should evaluate whether the PI and supporting staff have the necessary experience. Key questions include:

• How many clinical trials has the PI conducted in the past five years, and in which therapeutic areas?
• Has the PI received any regulatory inspection findings related to GCP?
• What is the average turnover rate of study coordinators and research nurses?
• What GCP training and certification do staff currently hold?

For example, a PI with ten oncology trials completed but with multiple FDA Form 483 citations may be a higher risk compared to a less experienced PI with a clean regulatory record. Feasibility questionnaires should capture such nuances.

Infrastructure and Technology Questions

Infrastructure capability directly influences trial quality. For complex trials requiring bioanalytical testing, imaging, or cold-chain management, questionnaires must go beyond basic facilities inquiries. Sample questions include:

• Does the site have validated -80°C freezers with continuous temperature monitoring?
• Are backup power systems in place to safeguard sample integrity?
• Is the site equipped with validated software for electronic data capture (EDC)?
• Are laboratory instruments calibrated according to international standards (e.g., ISO 15189)?

Some questionnaires include sample validation parameters such as:

These details help sponsors differentiate between sites that claim readiness and those that are genuinely prepared for trial operations.

Regulatory and Ethics Questions

Finally, feasibility questionnaires must assess local regulatory and ethics environments. Delays in IRB/EC approvals are a common reason for missed trial timelines. Essential questions include:

• What is the average IRB/EC review timeline for clinical trials at your institution?
• Do you have prior experience submitting to regulatory authorities such as FDA, EMA, CDSCO, or PMDA?
• Are there institutional policies restricting enrollment of vulnerable populations?

For example, if a site reports an average of 45 days for ethics approvals, sponsors can plan activation timelines accordingly. Sites with extended timelines (e.g., >90 days) may not be suitable for fast-track studies.

Transition to Next Considerations

The above domains—patient recruitment, investigator experience, infrastructure, and regulatory landscape—form the backbone of feasibility questionnaires. However, sponsors must also evaluate validation of responses, data reliability, and strategies to prevent overpromising. These aspects will be explored in Part 2, with focus on case studies, pitfalls, and best practices for robust feasibility planning.

Validating Feasibility Questionnaire Responses

Feasibility questionnaires are only useful if responses are accurate. Regulators and sponsors increasingly emphasize data verification as part of trial oversight. Sponsors must apply validation strategies to ensure that sites are not inflating capabilities or patient pools to secure trial participation.

One approach is to cross-verify patient pool estimates with hospital records, referral databases, or national disease registries. For example, if a site reports 500 annual cases of Type 2 diabetes, but regional public health data suggests only 300 cases, the sponsor should investigate. Similarly, sponsors should request anonymized patient counts or ICD-10 code reports to substantiate claims.

Case Study: Inflated Patient Recruitment Claims

A multinational sponsor faced delays in an oncology trial when three sites overestimated recruitment potential. While questionnaires projected 50 patients per site annually, actual enrollment was less than 10. Upon review, it was found that sites included patients outside inclusion criteria. This case underscores the importance of rigorous validation, including review of electronic health records (EHRs) and prior recruitment histories from registries such as ISRCTN Registry.

Common Pitfalls in Questionnaire Design

Despite best intentions, poorly designed questionnaires often result in incomplete or misleading data. Common pitfalls include:

• Overly generic questions that do not capture therapeutic-specific nuances
• Yes/No questions without quantitative context (e.g., “Do you have lab facilities?” instead of “How many calibrated centrifuges are available?”)
• Failure to include data validation fields or request supporting documentation
• Excessive questionnaire length leading to incomplete responses

To avoid these issues, sponsors should pilot-test questionnaires with selected sites and adjust based on feedback. Regulatory authorities also recommend focusing on essential questions that directly impact trial feasibility, rather than exhaustive lists that burden sites unnecessarily.

Best Practices for Effective Questionnaires

Effective feasibility questionnaires balance comprehensiveness with clarity. Best practices include:

• Tailoring questionnaires by therapeutic area (oncology, cardiology, infectious disease)
• Using a mix of quantitative and qualitative questions
• Integrating electronic platforms to streamline completion and analysis
• Embedding mandatory data validation checks (e.g., requiring supporting documentation uploads)

Some sponsors now deploy digital feasibility tools integrated with Clinical Trial Management Systems (CTMS). These allow automated scoring, comparison across sites, and identification of red flags such as inconsistent patient data. For example, an AI-enabled feasibility tool might score sites based on patient pool adequacy, infrastructure readiness, and regulatory history, generating a composite feasibility index for decision-making.

Sample Feasibility Scoring Framework

This weighted approach ensures objective decision-making while allowing customization for specific trial needs. For instance, in rare disease studies with small populations, patient recruitment weight might increase to 60%.

Conclusion

Feasibility questionnaires are a cornerstone of site selection and clinical trial planning. By including targeted questions on patients, investigators, infrastructure, and regulatory environment—and by validating responses through data cross-checks—sponsors can mitigate risks of underperformance and regulatory non-compliance. Effective design not only accelerates trial start-up but also strengthens inspection readiness by demonstrating a structured feasibility process.

Using Patient Registries to Streamline Rare Disease Trial Recruitment

Why Registries are Crucial in Rare Disease Research

Recruiting patients with rare diseases into clinical trials is exceptionally challenging due to their small, geographically dispersed populations. Traditional methods—mass advertising, physician referrals, or clinic-based outreach—rarely yield results in this context. Here, patient registries emerge as a powerful solution, enabling the identification of trial-eligible individuals from curated, disease-specific databases.

Registries collect and maintain structured clinical, genetic, and demographic data on individuals diagnosed or suspected of having a particular rare condition. These databases, often maintained by academic institutions, hospitals, or advocacy groups, serve both scientific and recruitment functions. For example, the International Niemann-Pick Disease Registry includes over 800 pre-consented patients, making it an invaluable tool for sponsors planning future interventional trials.

Types of Rare Disease Registries and Their Applications

Registries differ based on scope, ownership, and purpose. Understanding their classification helps sponsors and CROs align recruitment strategies accordingly:

• Patient-Powered Registries: Managed by advocacy groups with voluntary data entry by patients or caregivers
• Clinical Registries: Managed by hospitals, containing validated clinical, imaging, and biomarker data
• Genetic Registries: Focus on variant-specific populations, often tied to biobanks or labs
• Global/Consortium Registries: Managed by multi-institutional networks with harmonized data formats

Case example: The TREAT-NMD Global DMD Registry pools Duchenne muscular dystrophy data from over 30 countries, enabling pre-screening for trials with complex inclusion criteria such as exon-skipping eligibility.

Designing and Maintaining Effective Rare Disease Registries

For a registry to serve recruitment functions, it must meet certain quality benchmarks. Data should be standardized, longitudinal, and contain key variables such as mutation status, diagnostic confirmation, and functional scores (e.g., 6MWT, FVC, or ALSFRS-R).

Essential components include:

• Validated case definitions (e.g., clinical diagnosis plus genetic confirmation)
• Regular updates (at least annually) to track disease progression
• Fields indicating trial interest and contact preferences
• HIPAA/GDPR-compliant consent mechanisms

Sample Registry Data Structure:

Well-maintained registries also provide feasibility insights, such as patient density per site or anticipated dropout rates.

Registry-Based Pre-Screening and Site Selection

One of the most impactful uses of registries is in pre-screening. Trial protocols often have narrow inclusion criteria—like specific genotypes, functional scores, or organ involvement—that are nearly impossible to apply via public outreach. Registries allow sponsors to efficiently filter for these factors before contacting patients.

For instance, in a Batten disease trial requiring CLN6 mutations and seizure onset before age 3, the sponsor used a registry to identify 24 pre-qualified families globally, reducing site burden and recruitment time.

Additionally, registry data can help in:

• Selecting high-yield sites with dense patient clusters
• Forecasting screen failure rates
• Designing protocol amendments based on real-world baseline data

Integrating Electronic Health Records with Registries

Emerging tools enable real-time linkage between electronic health records (EHRs) and registries, enhancing the power of patient identification. With AI-driven matching algorithms, researchers can now receive alerts when a newly diagnosed patient fits an ongoing trial’s criteria.

Platforms like the Rare-X framework in the U.S. are working to bridge registries, EHRs, and sponsor portals in a secure, interoperable way. Benefits include:

• Reduced lag between diagnosis and trial outreach
• Dynamic eligibility verification
• Automated re-consent processes through digital platforms

While these integrations still face regulatory and data governance hurdles, their potential is transformative for ultra-rare disease trial acceleration.

Global Regulatory and Ethical Considerations in Registry Use

Using patient data from registries for recruitment must strictly comply with regional privacy laws like GDPR (Europe), HIPAA (U.S.), and the Data Protection Bill (India). Sponsors must ensure that:

• Data use agreements exist with registry owners
• Patients have explicitly opted in for trial contact
• De-identification and re-identification protocols are approved by IRBs

It’s also essential to maintain transparency with registry participants. Informing patients when their data has been used for pre-screening, and ensuring they have the right to decline participation, builds trust and safeguards ethical obligations.

In Japan, regulatory reforms now allow pre-screening via government-funded registries like those listed on RCT Portal Japan, further expanding global collaboration.

Partnering with Advocacy Group-Owned Registries

Many rare disease registries are initiated and maintained by patient advocacy groups. These groups act as custodians of sensitive patient data and require transparent, respectful engagement from sponsors. Benefits of collaboration include:

• Access to consented, engaged patient populations
• Patient-friendly recruitment workflows
• Joint educational campaigns to promote trial awareness

For example, the Global Foundation for Peroxisomal Disorders (GFPD) operates a registry linked with a companion Facebook support group. Trial sponsors gain both clinical data and trusted community access through partnership agreements.

Examples of Registry-Driven Trial Success

Several rare disease trials have significantly benefited from registry-based recruitment:

• SMA Expanded Access Study: Used Cure SMA’s registry to identify late-stage patients suitable for gene therapy EAP
• Morquio A Trial: Recruited over 80% of subjects from a multi-country MPS IVA registry
• Rare Cancer Basket Trial: Leveraged a genomic variant registry to fill mutation-matched cohorts

These examples underscore that registries not only speed up recruitment but also improve cohort quality and reduce screen failures.

Challenges and Limitations of Registry-Based Recruitment

Despite their promise, registries present some limitations:

• Data may be outdated or incomplete
• Limited geographic reach if not globally representative
• Consent statuses may expire or not include clinical contact permission
• Bias may exist if the registry population doesn’t reflect the full spectrum of disease severity

To mitigate these, sponsors should treat registries as dynamic, evolving resources—partnering for ongoing updates, re-engagement campaigns, and integration with clinical data sources.

Future Directions: AI, Blockchain, and Interoperability

Innovations are on the horizon to make rare disease registries even more effective:

• AI-Powered Matching: Smart algorithms that score patients based on probabilistic inclusion
• Blockchain Consent Systems: Allow real-time tracking and revocation of patient consent
• Global Interoperability: Efforts like IRDiRC and Global Rare Disease Registries aim to create unified access

These technologies promise to make the recruitment of patients with even the rarest conditions more feasible, ethical, and efficient.

Conclusion: Maximizing the Recruitment Potential of Registries

Patient registries are indispensable in rare disease clinical development. When designed, maintained, and ethically utilized, they offer unparalleled access to well-characterized, engaged patient populations. By partnering with registry owners, aligning with regulatory expectations, and integrating emerging technologies, sponsors can dramatically improve recruitment timelines, trial feasibility, and patient outcomes.